{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:38:14Z","timestamp":1773779894093,"version":"3.50.1"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fudan-Fosun Research Fund","award":["FNF202329"],"award-info":[{"award-number":["FNF202329"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patent foramen ovale occurs in approximately 25% of cryptogenic stroke patients, with paradoxical embolization representing a key pathophysiological mechanism. While recent trials have established the clinical efficacy of percutaneous PFO closure in reducing recurrent stroke risk, comprehensive economic evaluation within the Chinese healthcare framework remains limited. This study assessed the cost-effectiveness of PFO closure compared with medical therapy alone in Chinese patients with cryptogenic stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Markov cohort model was constructed with four health states (stable, post-minor recurrent stroke, post-moderate-to-severe recurrent stroke, death) using 3-month cycles over a 30-year horizon. The analysis adopted a Chinese healthcare payer perspective, incorporating transition probabilities derived primarily from the RESPECT trial extended follow-up data and Chinese-specific cost data from multi-center hospital surveys. Primary outcome was the incremental cost-effectiveness ratio (ICER) evaluated against China\u2019s willingness-to-pay threshold of $37,654 per quality-adjusted life year (QALY). Extensive sensitivity analyses examined parameter uncertainty and model robustness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PFO closure demonstrated economic dominance over medical therapy, yielding 1.41 additional QALYs (13.42 vs 12.01) while reducing lifetime costs by $4,045 per patient ($8,847 vs $12,892). The resulting negative ICER of -$2,868 per QALY indicated superior outcomes at lower cost. Probabilistic sensitivity analysis revealed 94.2% probability of cost-effectiveness at the Chinese threshold. One-way sensitivity analyses consistently showed negative ICERs across all parameter ranges, with time horizon and psychological comorbidity costs exerting the greatest influence on results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the Chinese healthcare context, PFO closure represents a dominant economic strategy for cryptogenic stroke patients, providing both clinical benefits and cost savings. These findings support broader implementation of PFO closure programs and inform evidence-based resource allocation decisions for stroke prevention services.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0345015","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:23:11Z","timestamp":1773768191000},"page":"e0345015","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of percutaneous patent foramen ovale closure versus medical therapy for cryptogenic stroke prevention: A Chinese healthcare perspective"],"prefix":"10.1371","volume":"21","author":[{"given":"Chen","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhujun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9881-3031","authenticated-orcid":true,"given":"Xiaoli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"issue":"4","key":"pone.0345015.ref001","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1474-4422(13)70310-7","article-title":"Embolic strokes of undetermined source: the case for a new clinical construct","volume":"13","author":"RG Hart","year":"2014","journal-title":"Lancet Neurol"},{"issue":"4","key":"pone.0345015.ref002","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1161\/STROKEAHA.108.529883","article-title":"Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry","volume":"40","author":"J Putaala","year":"2009","journal-title":"Stroke"},{"issue":"1","key":"pone.0345015.ref003","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0025-6196(12)60336-X","article-title":"Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts","volume":"59","author":"PT Hagen","year":"1984","journal-title":"Mayo Clin Proc"},{"issue":"18","key":"pone.0345015.ref004","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJM198805053181802","article-title":"Prevalence of patent foramen ovale in patients with stroke","volume":"318","author":"P Lechat","year":"1988","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0345015.ref005","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1610057","article-title":"Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke","volume":"377","author":"JL Saver","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0345015.ref006","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","article-title":"Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke","volume":"377","author":"JL Mas","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0345015.ref007","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1707404","article-title":"Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke","volume":"377","author":"L S\u00f8ndergaard","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0345015.ref008","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008356","article-title":"Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study","volume":"7","author":"G Turc","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"pone.0345015.ref009","doi-asserted-by":"crossref","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association\/American Stroke Association","volume":"52","author":"DO Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"38","key":"pone.0345015.ref010","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1093\/eurheartj\/ehy649","article-title":"European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism","volume":"40","author":"C Pristipino","year":"2019","journal-title":"Eur Heart J"},{"issue":"10","key":"pone.0345015.ref011","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.amjcard.2014.08.027","article-title":"Cost effectiveness of percutaneous closure versus medical therapy for cryptogenic stroke in patients with a patent foramen ovale","volume":"114","author":"CA Pickett","year":"2014","journal-title":"Am J Cardiol"},{"issue":"7","key":"pone.0345015.ref012","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcin.2012.02.021","article-title":"Meta-analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism","volume":"5","author":"S Agarwal","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"issue":"3","key":"pone.0345015.ref013","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/svn-2020-000457","article-title":"China Stroke Statistics 2019: A Report From the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations","volume":"5","author":"Y-J Wang","year":"2020","journal-title":"Stroke Vasc Neurol"},{"key":"pone.0345015.ref014","volume-title":"Report on Cardiovascular Health and Diseases in China 2020","author":"SS Hu","year":"2021"},{"issue":"9","key":"pone.0345015.ref015","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/hs0901.094253","article-title":"Long-term survival and causes of death after stroke","volume":"32","author":"Danish MONICA Study Group","year":"2001","journal-title":"Stroke"},{"issue":"5","key":"pone.0345015.ref016","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0272989X12458348","article-title":"Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6","volume":"32","author":"AH Briggs","year":"2012","journal-title":"Med Decis Making"},{"issue":"9","key":"pone.0345015.ref017","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(15)00132-5","article-title":"Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study","volume":"14","author":"L Li","year":"2015","journal-title":"Lancet Neurol"},{"issue":"1","key":"pone.0345015.ref018","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13561-025-00650-7","article-title":"Impact of China Guidelines for Pharmacoeconomic Evaluations on study quality: a systematic review of economic evaluations in China","volume":"15","author":"S Cao","year":"2025","journal-title":"Health Econ Rev"},{"issue":"1","key":"pone.0345015.ref019","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/00019053-200725010-00002","article-title":"Rates and probabilities in economic modelling: transformation, translation and appropriate application","volume":"25","author":"RL Fleurence","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"pone.0345015.ref020","article-title":"Trends in China\u2019s total health expenditure from 2000 to 2021 and spatial distribution characteristics and driving factors of out-of-pocket health expenditure","author":"YY Yang","year":"2024","journal-title":"Lanzhou University"},{"issue":"1","key":"pone.0345015.ref021","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1186\/s12913-021-07010-1","article-title":"Economic burden of comorbid chronic conditions among survivors of stroke in China: 10-year longitudinal study","volume":"21","author":"J Zhang","year":"2021","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"pone.0345015.ref022","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1474-4422(18)30500-3","article-title":"Stroke in China: advances and challenges in epidemiology, prevention, and management","volume":"18","author":"S Wu","year":"2019","journal-title":"Lancet Neurol"},{"issue":"6","key":"pone.0345015.ref023","doi-asserted-by":"crossref","first-page":"464","DOI":"10.5582\/bst.2019.01339","article-title":"Progress on drug pricing negotiations in China","volume":"13","author":"M Tang","year":"2020","journal-title":"Biosci Trends"},{"issue":"1","key":"pone.0345015.ref024","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/neurintsurg-2021-018420","article-title":"Economic evaluation of intravenous alteplase for stroke with the time of onset between 4.5 and 9 hours","volume":"15","author":"J Chen","year":"2023","journal-title":"J Neurointerv Surg"},{"issue":"6","key":"pone.0345015.ref025","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s11136-015-1196-z","article-title":"Validity, responsiveness, and minimal clinically important difference of EQ-5D-5L in stroke patients undergoing rehabilitation","volume":"25","author":"P Chen","year":"2016","journal-title":"Qual Life Res"},{"issue":"1","key":"pone.0345015.ref026","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12955-023-02194-y","article-title":"Socioeconomic status and health-related quality of life after stroke: a systematic review and meta-analysis","volume":"21","author":"YA Sun","year":"2023","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"pone.0345015.ref027","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1080\/13696998.2018.1456445","article-title":"Cost-effectiveness of percutaneous patent foramen ovale closure as secondary stroke prevention","volume":"21","author":"DL Tirschwell","year":"2018","journal-title":"J Med Econ"},{"issue":"3","key":"pone.0345015.ref028","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1212\/WNL.0000000000000589","article-title":"Recurrent stroke predictors differ in medically treated patients with pathogenic vs. other PFOs","volume":"83","author":"DE Thaler","year":"2014","journal-title":"Neurology"},{"issue":"4","key":"pone.0345015.ref029","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/hec.985","article-title":"Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra","volume":"14","author":"K Claxton","year":"2005","journal-title":"Health Econ"},{"issue":"6","key":"pone.0345015.ref030","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/(SICI)1099-1050(199611)5:6<513::AID-HEC237>3.0.CO;2-9","article-title":"An economic approach to clinical trial design and research priority-setting","volume":"5","author":"K Claxton","year":"1996","journal-title":"Health Econ"},{"issue":"4","key":"pone.0345015.ref031","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/STROKEAHA.108.540781","article-title":"Sex differences in stroke epidemiology: a systematic review","volume":"40","author":"P Appelros","year":"2009","journal-title":"Stroke"},{"issue":"4","key":"pone.0345015.ref032","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jamainternmed.2016.0166","article-title":"Coronary Catheterization and Percutaneous Coronary Intervention in China: 10-Year Results From the China PEACE-Retrospective CathPCI Study","volume":"176","author":"X Zheng","year":"2016","journal-title":"JAMA Intern Med"},{"key":"pone.0345015.ref033","doi-asserted-by":"crossref","first-page":"1016854","DOI":"10.3389\/fpubh.2022.1016854","article-title":"Patent foramen ovale closure vs. medical therapy alone after cryptogenic stroke in China: A cost-effectiveness analysis","volume":"10","author":"N Wei","year":"2022","journal-title":"Front Public Health"},{"issue":"20","key":"pone.0345015.ref034","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1212\/WNL.0000000000009443","article-title":"Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology","volume":"94","author":"SR Mess\u00e9","year":"2020","journal-title":"Neurology"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0345015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:23:18Z","timestamp":1773768198000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0345015"}},"subtitle":[],"editor":[{"given":"Jeerath","family":"Phannajit","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0345015","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}